HMP-203.1

IN THE CLAIMS

Please cancel claims 1-59.

Please add new claims 60-79 as follows:

- 60. An pharmaceutical formulation in oral unit dosage form, comprising Glutathione, said formulation being in such form adapted to modify vascular tone in an organism administered said formulation.
- 61. The formulation according to claim 1, wherein the formulation acts as a vasodilator through alteration of nitric oxide metabolism.
- 62. The formulation method according to claim 1, wherein the formulation is effective for treating pathological vasospasm.
- 63. The method according to claim 1, wherein the formulation is effective for treating sexual dysfunction.
- 64. The formulation according to claim 1, in combination with a drug effective to treat congestive heart failure.
- 65. The formulation according to claim 1, further comprising a physiologic nitric oxide precursor.

- 2 - 02/25/02

- 66. The formulation according to claim 6, wherein the nitric oxide precursor is arginine.
- 67. The formulation according to claim 6, wherein said formulation comprises about 500 mg reduced L-glutathione, about 200 mg ascorbic acid, and about 200 mg arginine.
- 68. The formulation according to claim 6, wherein the nitric oxide precursor comprises a pharmaceutically acceptable vasodilator.
- 69. The formulation according to claim 6, wherein the nitric oxide precursor comprises an NO₂ functionality.
- 70. The formulation according to claim 10, wherein the nitric oxide precursor comprises an organic nitrate.
- 71. The formulation according to claim 1, further comprising an antibiotic agent.
- 72. A pharmaceutical composition in oral unit dosage form, comprising in combination glutathione and an antiviral or antimicrobial antibiotic agent.

- 73. The pharmaceutical composition according to claim 13, wherein said antibiotic agent comprises an antibiotic having activity against mycoplasma infection.
- 74. The pharmaceutical composition according to claim 13, wherein said antibiotic agent comprises an antibiotic having activity against viral infection.
- 75. The pharmaceutical composition according to claim 13, wherein said antimicrobial agent comprises an antibiotic in sufficient amount to suppress growth of a microbe and said glutathione is provided in sufficient amount to control free radical reactions associated with the microbe.
- 76. The pharmaceutical composition according to claim 13, wherein said composition is provided in an oral dosage form
- 77. The pharmaceutical composition according to claim 13, wherein said antibiotic agent comprises an aminoglycoside.
- 78. The pharmaceutical composition according to claim 13, wherein said antibiotic agent comprises a quinolone antibiotic.
- 79. The pharmaceutical composition according to claim 13, wherein said formulation is adapted to modify vascular tone in an organism administered said formulation.

HMP-203.1 - 4 - 02/25/02